Ann: December Quarterly Appendix 4C, page-8

I think yesterdays trading started to look like the selling of someone who knows they are about to get another discounted allocation and was happy to take a 20% profit on their last allocation to finance the next one.

So a gap finance issue could be nearer than we think.

All these stopgaps do make me wonder how the company is so confident that on FDA clearance our fortunes will turn around? Surely with the calibre of appointments of late they aren't just throwing hail Mary passes.

Either the IPO finance is already at agreed in principle terms or there must be some bulk purchase orders already in place for Pulse.